119 related articles for article (PubMed ID: 27693049)
1. The antiangiogenic and antitumor activities of the N-terminal fragment of endostatin augmented by Ile/Arg substitution: The overall structure implicated the biological activity.
Chamani R; Asghari SM; Alizadeh AM; Mansouri K; Doroudi T; Kolivand PH; Ghafouri H; Ehtesham S; Rabouti H; Mehrnejad F
Biochim Biophys Acta; 2016 Dec; 1864(12):1765-1774. PubMed ID: 27693049
[TBL] [Abstract][Full Text] [Related]
2. Effect of Disulfide Bond Incorporation on the Structure and Activity of Endostatin Peptide.
Ehtesham S; Sariri R; Eidi A; Hosseinkhani S
Biochemistry (Mosc); 2018 Nov; 83(11):1388-1398. PubMed ID: 30482150
[TBL] [Abstract][Full Text] [Related]
3. Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: Mechanistic and therapeutic insights.
Chamani R; Asghari SM; Alizadeh AM; Eskandari S; Mansouri K; Khodarahmi R; Taghdir M; Heidari Z; Gorji A; Aliakbar A; Ranjbar B; Khajeh K
Vascul Pharmacol; 2015 Sep; 72():73-82. PubMed ID: 26187352
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X
PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141
[TBL] [Abstract][Full Text] [Related]
5. Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide.
Yin R; Zheng H; Xi T; Xu HM
Bioconjug Chem; 2010 Jul; 21(7):1142-7. PubMed ID: 20515045
[TBL] [Abstract][Full Text] [Related]
6. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis of the N-terminal fragment of the antiangiogenic protein endostatin: a molecular dynamics study.
Torres PH; Sousa GL; Pascutti PG
Proteins; 2011 Sep; 79(9):2684-92. PubMed ID: 21769939
[TBL] [Abstract][Full Text] [Related]
8. The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin.
Lim J; Duong T; Lee G; Seong BL; El-Rifai W; Ruley HE; Jo D
Biomaterials; 2013 Aug; 34(26):6261-71. PubMed ID: 23714245
[TBL] [Abstract][Full Text] [Related]
9. RGD-modified endostatin fragments showed an antitumor effect through antiangiogenesis.
Pu CY; Xu HM; Hu JL; Zheng H; Huang XF; Zhang C; Yang YJ; Li YB
Anticancer Drugs; 2012 Sep; 23(8):788-802. PubMed ID: 22555196
[TBL] [Abstract][Full Text] [Related]
10. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent.
Cho H; Kim WJ; Lee YM; Kim YM; Kwon YG; Park YS; Choi EY; Kim KW
Oncol Rep; 2004 Jan; 11(1):191-5. PubMed ID: 14654925
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas.
Ding I; Sun JZ; Fenton B; Liu WM; Kimsely P; Okunieff P; Min W
Cancer Res; 2001 Jan; 61(2):526-31. PubMed ID: 11212245
[TBL] [Abstract][Full Text] [Related]
12. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.
Shin SU; Cho HM; Merchan J; Zhang J; Kovacs K; Jing Y; Ramakrishnan S; Rosenblatt JD
Mol Cancer Ther; 2011 Apr; 10(4):603-14. PubMed ID: 21393427
[TBL] [Abstract][Full Text] [Related]
14. Zinc-binding of endostatin is essential for its antiangiogenic activity.
Boehm T; O'reilly MS; Keough K; Shiloach J; Shapiro R; Folkman J
Biochem Biophys Res Commun; 1998 Nov; 252(1):190-4. PubMed ID: 9813168
[TBL] [Abstract][Full Text] [Related]
15. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity.
Tjin Tham Sjin RM; Satchi-Fainaro R; Birsner AE; Ramanujam VM; Folkman J; Javaherian K
Cancer Res; 2005 May; 65(9):3656-63. PubMed ID: 15867360
[TBL] [Abstract][Full Text] [Related]
16. The COOH-terminal globular domain of fibrinogen gamma chain suppresses angiogenesis and tumor growth.
Akakura N; Hoogland C; Takada YK; Saegusa J; Ye X; Liu FT; Cheung AT; Takada Y
Cancer Res; 2006 Oct; 66(19):9691-7. PubMed ID: 17018627
[TBL] [Abstract][Full Text] [Related]
17. Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities.
Chillemi F; Francescato P; Ragg E; Cattaneo MG; Pola S; Vicentini L
J Med Chem; 2003 Sep; 46(19):4165-72. PubMed ID: 12954068
[TBL] [Abstract][Full Text] [Related]
18. Improved biological activity of a mutant endostatin containing a single amino-acid substitution.
Yokoyama Y; Ramakrishnan S
Br J Cancer; 2004 Apr; 90(8):1627-35. PubMed ID: 15083196
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.
Ren Z; Wang Y; Jiang W; Dai W; Jiang Y
PLoS One; 2014; 9(9):e107823. PubMed ID: 25229620
[TBL] [Abstract][Full Text] [Related]
20. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells.
Dkhissi F; Lu H; Soria C; Opolon P; Griscelli F; Liu H; Khattar P; Mishal Z; Perricaudet M; Li H
Hum Gene Ther; 2003 Jul; 14(10):997-1008. PubMed ID: 12869217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
